Publicaciones en las que colabora con Diego Serrano Tejero (20)

2023

  1. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

    Cancers, Vol. 15, Núm. 12

  2. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  3. Presence of Activated (Phosphorylated) STAT3 in Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists

    Biomedicines, Vol. 10, Núm. 7

  2. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

  3. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

  4. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  2. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

  3. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  4. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

  5. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Drugsniper, a tool to exploit loss-of-function screens, identifies CREBBP as a predictive biomarker of VOLASERTIB in small cell lung carcinoma (SCLC)

    Cancers, Vol. 12, Núm. 7, pp. 1-18

  2. Repeated stereotactic radiosurgery for recurrent brain metastases: An effective strategy to control intracranial oligometastatic disease

    Critical Reviews in Oncology/Hematology, Vol. 153

2013

  1. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFΒ1-targeting peptides P17 and P144

    Experimental Cell Research, Vol. 319, Núm. 3, pp. 12-22

  2. Multiscale in situ analysis of the role of dyskerin in lung cancer cells

    Integrative Biology (United Kingdom), Vol. 5, Núm. 2, pp. 402-413

2011

  1. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer

    Molecular Cancer, Vol. 10

2010

  1. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop

    Experimental Cell Research, Vol. 316, Núm. 4, pp. 554-567

2009

  1. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

    British Journal of Cancer, Vol. 100, Núm. 6, pp. 932-940

2007

  1. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1197-1204